Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the ...

Alphatec Holdings, Theradaptive ink marketing partnership for breakthrough regenerative technology in spinal fusion: Carlsbad, California Wednesday, January 14, 2026, 13:00 Hrs [I ...

Discover how advanced detectors are driving improvements in biopharma quality assurance by enhancing precision across ...

Celltrion outlines a blueprint for innovative drug development built on its antibody expertise The company highlights its ...

Alphatec Holdings, Inc. , a provider of innovative solutions dedicated to revolutionizing spine surgery, and Theradaptive, Inc., a clinical-stage regenerative medicine company pioneering engineered ...

On November 2, 2025, the research group led by Dr. Zeng Ling from Army Medical University systematically elucidated the molecular mechanisms, ...

Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.

ATEC Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Major Strategic Alignment Theradaptive Initiates Series B to Advance Proprietary Protein-Engineering Technology ...

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...

Research efforts are ongoing to develop safer, broad-spectrum antivenoms. Technology Networks sat down with Dr. Andreas ...

Charles River Laboratories International, Inc. today announced two planned acquisitions of K.F. (Cambodia) Ltd. and PathoQuest SAS; the addition of Dr. Namandjé N. Bumpus as Chief Scientific and ...

Fannin Partners has been awarded a $300,000 Phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) to advance a first-in-class, non-VEGF–targeted therapeutic for ...